Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Out-Licensing > SPI-392

SPI-392: Schizophrenia

Target Indications

  • Schizophrenia

Route of Administration

  • Oral

Status

  • Preclinical

Activity Profile

In animal studies to date:

  • Reverses phencyclidine-induced disruption of pre-pulse inhibition (psychosis model)
  • Disrupts conditioned avoidance responding (cognition model)
  • Novel receptor profile as compared to the currently available antipsychotics
  • Data suggests that this compound is a D4-dopaminergic receptor antagonist and a 5-HT1A-serotonergic receptor agonist
  • Good safety profile and therapeutic index

1. http://www.schizophrenia.com/szfacts.htm#

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Market Opportunities

SPI-1620

Schizophrenia Market

An estimated 2 million Americans or 1% of the American population is affected by schizophrenia1. Both men and women are affected in equal numbers, although onset is slightly later in women. People with schizophrenia suffer severe disturbances in thinking, social and emotions such as hearing internal voices not heard by others, or believing that other people are reading their minds, controlling their thoughts or plotting to harm them.

While there are available treatments that can relieve some of the symptoms, these medications cause significant side effects such as involuntary motor activity, weight gain, and social withdrawal.